UBS Group’s NRX Pharmaceuticals NRXP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.73M | Buy |
423,115
+397,888
| +1,577% | +$1.31M | ﹤0.01% | 5235 |
|
|
2026
Q1 | $53.7K | Buy |
25,227
+21,689
| +613% | +$43.8K | ﹤0.01% | 7326 |
|
|
2025
Q4 | $9.59K | Sell |
3,538
-149,310
| -98% | -$401K | ﹤0.01% | 8270 |
|
|
2025
Q3 | $504K | Buy |
152,848
+31,240
| +26% | +$89.4K | ﹤0.01% | 6090 |
|
|
2025
Q2 | $396K | Buy |
121,608
+121,503
| +115,717% | +$305K | ﹤0.01% | 6204 |
|
|
2025
Q1 | $215 | Sell |
105
-45
| -30% | -$127 | ﹤0.01% | 9880 |
|
|
2024
Q4 | $330 | Buy |
150
+112
| +295% | +$151 | ﹤0.01% | 9514 |
|
|
2024
Q3 | $64 | Sell |
38
-1,049
| -97% | -$2.11K | ﹤0.01% | 9214 |
|
|
2024
Q2 | $2.65K | Sell |
1,087
-570
| -34% | -$2.03K | ﹤0.01% | 8319 |
|
|
2024
Q1 | $7.82K | Sell |
1,657
-3,027
| -65% | -$13.9K | ﹤0.01% | 7361 |
|
|
2023
Q4 | $21.5K | Buy |
4,684
+4,563
| +3,771% | +$15.1K | ﹤0.01% | 7061 |
|
|
2023
Q3 | $315 | Sell |
121
-155
| -56% | -$516 | ﹤0.01% | 8591 |
|
|
2023
Q2 | $1.33K | Sell |
276
-1,585
| -85% | -$9.53K | ﹤0.01% | 7943 |
|
|
2023
Q1 | $12.3K | Buy |
1,861
+1,822
| +4,672% | +$18.5K | ﹤0.01% | 7453 |
|
|
2022
Q4 | $433 | Buy |
+39
| New | +$393 | ﹤0.01% | 10181 |
|
|
2022
Q3 | – | Sell |
-1,680
| Closed | -$10K | – | 10728 |
|
|
2022
Q2 | $10K | Buy |
1,680
+1,227
| +271% | +$16.1K | ﹤0.01% | 7978 |
|
|
2022
Q1 | $11K | Sell |
453
-721
| -61% | -$23.5K | ﹤0.01% | 8308 |
|
|
2021
Q4 | $56K | Buy |
+1,174
| New | +$84.7K | ﹤0.01% | 6796 |
|
|
2021
Q3 | – | Sell |
-839
| Closed | -$97K | – | 9902 |
|
|
2021
Q2 | $97K | Buy |
+839
| New | +$221K | ﹤0.01% | 5905 |
|
|
2021
Q1 | – | Sell |
-23
| Closed | -$6K | – | 9319 |
|
|
2020
Q4 | $6K | Sell |
23
-23
| -50% | -$3.78K | ﹤0.01% | 7766 |
|
|
2020
Q3 | $5K | Sell |
46
-37
| -45% | -$3.98K | ﹤0.01% | 7317 |
|
|
2020
Q2 | $9K | Sell |
83
-120
| -59% | -$13.1K | ﹤0.01% | 7086 |
|
|
2020
Q1 | $22K | Buy |
203
+30
| +17% | +$3.21K | ﹤0.01% | 6439 |
|
|
2019
Q4 | $18K | Buy |
173
+20
| +13% | +$2.11K | ﹤0.01% | 6946 |
|
|
2019
Q3 | $16K | Sell |
153
-174
| -53% | -$18.2K | ﹤0.01% | 6877 |
|
|
2019
Q2 | $34K | Sell |
327
-83
| -20% | -$8.63K | ﹤0.01% | 6237 |
|
|
2019
Q1 | $42K | Buy |
+410
| New | +$42.1K | ﹤0.01% | 5688 |
|
|
2018
Q3 | – | Sell |
-130
| Closed | -$13K | – | 8158 |
|
|
2018
Q2 | $13K | Hold |
130
| – | – | ﹤0.01% | 6990 |
|
|
2018
Q1 | $13K | Buy |
+130
| New | +$12.7K | ﹤0.01% | 6720 |
|
Other funds holding NRXP
BGI
AI
UBS Group's NRXP Position: Q2 2026 in Review
UBS Group increased its NRX Pharmaceuticals (NRXP) stake by 1,577% in Q2 2026, buying an estimated $1.31M and bringing the position to 423,115 shares worth $1.73M. The position accounts for ﹤0.01% of the portfolio, ranked #5235.
UBS Group first reported a position in NRXP in Q1 2018 and has held it in 29 quarters since. 46 funds tracked by Wall St. Rank hold NRXP as of Q2 2026.
- UBS Group held 423,115 shares of NRX Pharmaceuticals worth $1.73M as of Q2 2026.
- UBS Group bought 397,888 NRX Pharmaceuticals shares in Q2 2026, an estimated $1.31M.
- NRX Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5235 holding.
- UBS Group first reported a position in NRX Pharmaceuticals in Q1 2018 and has held it in 29 quarters since.
- 46 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.